REG - Genflow Biosciences - Admittance to trading on the OTCQB Venture Market

Genflow BiosciencesAnnouncement

13/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230613:nRSM4646Ca&default-theme=true

RNS Number : 4646C  Genflow Biosciences PLC  13 June 2023

 

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

Anti-Ageing Company, Genflow Biosciences, Announces Listing on OTCQB Venture
Market

in addition to its LSE Main Market Listing

 

Genflow has 3 Gene Therapies in Development Seeking to Treat NASH and Werner
Syndrome

 

Genflow Biosciences Plc ("Genflow" or "the Company") is pleased to announce
that, after a successful application process, its Ordinary Shares ("Ordinary
Shares") begin trading on the OTCQB Venture Market in the United States ("US")
today under the symbol GENFF.   Genflow will continue to trade on the London
Stock Exchange ("LSE") Main Market under the symbol GENF, and, importantly,
the onboarding to this additional U.S. securities trading platform does not
involve any capital raise.  The new U.S. trading facility expands access to a
broader pool of investors and enables investors in the United States to trade
during U.S. trading hours and in U.S. dollars.

 

Eric Leire, CEO of Genflow, expressed his excitement about this significant
achievement, stating, "We are thrilled to announce that Genflow Biosciences
has been admitted to trading on the OTCQB Venture Market in the United States.
This move not only expands our reach to a larger investor base and has the
potential to enhance liquidity for our shares, but also reinforces our
unwavering commitment to our primary listing on the prestigious London Stock
Exchange."

 

Tamara Joseph, Chair of the Board, also expressed her enthusiasm on behalf of
the Board of Directors, saying, "Genflow is developing gene therapies that
could address an important source of many global illnesses:  aging.  As the
Company moves into Phase I/II clinical trials to treat potentially the orphan
condition Werner Syndrome, which causes premature aging, and NASH, a liver
disease that affects an estimated 35 million people around the world, it is
the right time to retain our London Stock Exchange listing while adding easier
access for US investors."

 

Further information on Genflow's application and the OTCQB market is below:

 

As a Foreign Private Issuer, Genflow's admission to the OTC Markets is subject
to meeting the requirements for OTCQB, which apply to international reporting
companies. This includes fulfilling the criteria for exemption under the US
Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption
includes the disclosure obligation to ensure that certain information made
public or distributed under home market regulations is made publicly available
on the Company's website or other electronic information delivery system in
English. Thus, the Company will have no additional reporting obligations and
incur minimal ongoing costs; admission to the OTC Markets is subject to
meeting the requirements for OTCQB, which apply to international reporting
companies.

 

This includes fulfilling the criteria for exemption under the US Exchange Act
Rule 12g3-2(b) from SEC reporting. Under this exemption, the Company must
ensure that information made public or distributed under its home market
regulations is made available to the public on its website or another
electronic information delivery system in English. Consequently, Genflow will
have no additional reporting obligations and will incur minimal ongoing costs
compared to traditional major exchanges.

 

As a verified market, the OTCQB offers transparent trading for companies that
have met a minimum bid price test, are current in their financial reporting
and have undergone an annual verification and management certification
process.

 

The cross-trading facility is provided through OTC Markets Group Inc., located
in New York. OTC Markets operates the world's largest electronic interdealer
quotation system for US broker-dealers and offers multiple media channels to
increase the visibility of OTC-listed companies. Online brokers such as
Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all
offer OTCQB trades. US investors can find real-time quotes, market information
and access current company news and developments on a BSF page on the OTC
Markets website at www.otcmarkets.com.

 

Genflow appointed the corporate securities law firm Galanopoulos & Company
as its OTCQB Sponsor to support its onboarding to the OTCQB Venture Market.

 

Additional information about the OTCQB market can be found at:
www.otcmarkets.com/learn/market-101
(http://www.otcmarkets.com/learn/market-101)

 

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

 Genflow Biosciences Plc
 Dr Eric Leire             +32 477 495 881

 Chief Executive Officer

 Clear Capital Markets
 Corporate Broker          +44 203 869 6080

 Andrew Blaylock

 

Genflow Biosciences: Advancing Longevity and Healthspan

Genflow Biosciences is a UK-based biotechnology company established in 2020.
The company focuses on developing gene therapies that target the aging process
and aim to reduce and delay age-related diseases. Their approach involves
using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6
(SIRT6) gene variant found in centenarians to cells.

Genflow's mission is to increase the understanding of factors that control and
impact lifespan. They research, develop, and commercialize therapeutic
solutions to extend healthspan, enabling longer and healthier lives. Genflow
is dedicated to developing and commercializing novel therapeutics for aging in
both dogs and humans. By addressing aging, Genflow aims to decrease healthcare
costs and alleviate the emotional and societal burden associated with an aging
population.

 

For more information, please visit www.genflowbio.com
(http://www.genflowbio.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPURGQUPWGMP